APA (7th ed.) Citation

MD, R., C, S., E, A., O, A., CKD, C., V, P., . . . JB, G. (2023). JAK inhibitors and the risk of malignancy: A meta-analysis across disease indications. Annals of the rheumatic diseases, 82(8), 1059. https://doi.org/10.1136/ard-2023-224049

Chicago Style (17th ed.) Citation

MD, Russell, et al. "JAK Inhibitors and the Risk of Malignancy: A Meta-analysis Across Disease Indications." Annals of the Rheumatic Diseases 82, no. 8 (2023): 1059. https://doi.org/10.1136/ard-2023-224049.

MLA (9th ed.) Citation

MD, Russell, et al. "JAK Inhibitors and the Risk of Malignancy: A Meta-analysis Across Disease Indications." Annals of the Rheumatic Diseases, vol. 82, no. 8, 2023, p. 1059, https://doi.org/10.1136/ard-2023-224049.